Find the products and resources you are looking for!
Get in touch!
Our local employees are always happy to answer your questions. Highly trained and experienced teams in your country can provide quick, helpful, and comprehensive support.
Miltenyi Biotec distribution:
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
Cookie Settings
We use cookies in order to provide the best possible website experience for you. This includes cookies that are technically required to ensure a proper functioning of the website, as well as cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for displaying personalized content. You are free to choose the categories you would like to permit. Please note that depending on your settings, the full functionality of the website may no longer be available. Further information can be found in our Privacy Statement.
Genetic modification of immune cells with “chimeric antigen receptors” (CARs) is one of the most promising concepts to treat cancer patients. Consequently, Miltenyi Biotec will facilitate the first German phase I clinical trial to treat melanoma patients with CAR T cells .The project consortium will also explore how automation can make this personalized form of therapy available to a large number of patients.
Patients' own T cells will be genetically modified in such a way that they recognize a specific surface molecule (CD20) on melanoma stem cells. This will enable the “CD20 CAR T cells” to specifically eradicate the tumor cells and thus contribute to cure the malignant disease. Central to the project is the CliniMACS Prodigy, an innovative device developed by Miltenyi Biotec that enables automated and safe manufacturing of the cellular products that will be applied to the patients.
Hannover Medical School, University of Cologne and Miltenyi Biotec as coordinator
Funded by the Federal Ministry of Education and Research, Fkz 01EK1507A
For more information visit the CD20 CAR-TIME website
Copyright © 2021 Miltenyi Biotec and/or its affiliates. All rights reserved.